Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors.
Nienke A de GlasEsther BastiaannetFrederiek van den BosSimon P MooijaartAstrid A M van der VeldtKarlijn P M SuijkerbuijkMaureen J B AartsFranchette W P J van den BerkmortelChristian U BlankMarye J Boers-SonderenAlfonsus J M van den EertweghJan-Willem B de GrootJohn B A G HaanenGeke A P HospersMathilde JalvingDjura PiersmaRozemarijn S van RijnAlbert J Ten TijeGerard VreugdenhilMichel W J M WoutersJohanneke E A PortieljeEllen H W KapiteijnPublished in: Cancers (2021)
Response rates and toxicity outcomes of checkpoint inhibitors did not change with increasing age or comorbidity. However, the impact of grade I-II toxicity on quality of life deserves further study as older patients discontinue treatment more frequently.